Schlieren and St. Gallen, Switzerland, December 10, 2020 - The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced that Prof. Dr. med. Wolfang Korte who leads the Center for Laboratory Medicine will present new data from the implementation of Proclarix® in their laboratory routine at AACC’s annual scientific meeting & clinical lab expo.
The first poster presentations (B-329) will demonstrate that the automation of Proclarix®, a next-generation prostate cancer test to support biopsy decision making, reveals high precision, accuracy and ease of use in real-world laboratory settings. The second poster presentations (B-330) will illustrate that the Risk Score of Proclarix® shows high reproducibility in routine use.
The following ePosters and related audio files will be available to attendees in AACC’s virtual meeting platform from December 13, 2020 to January 1, 2021:
Poster B-329: Jentsch et al. Analytical performance of automated thrombospondin-1 and cathepsin D immunoassays for prostate cancer risk assessment. Presenter: Prof. Dr. med. Wolfgang Korte
Poster B-330: Turnher et al. Analytical validation of the Proclarix Risk Score for the diagnosis of prostate cancer. Presenter: Prof. Dr. med. Wolfgang Korte
About Proclarix®
Proclarix® is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.
About ZLM
The Center for Laboratory Medicine St. Gallen is an ISO/IEC17025 accredited clinical laboratory in St. Gallen Switzerland. The ZLM delivers high quality diagnostic services to the Cantonal Hospital St. Gallen, public hospitals and a large number of general practitioners and urologists in Eastern Switzerland as well specialized laboratory research services to research groups worldwide. The ZLM has more than 200 motivated and highly trained staff members and a longstanding expertise in the areas of clinical chemistry, hematology, immunology, microbiology, and genetics with a menu of more than 1500 tests. Visit www.zlmsg.ch for more information. To secure adequate logistics for Proclarix® testing, please contact us via info@zlmsg.ch.
For questions on laboratory services, please contact:
Prof. Dr. med. Wolfgang Korte, CEO, ZLM
info@zlmsg.ch, +41 58 580 92 00
About Proteomedix
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the European market early 2020. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.
For further details, please contact:
Christian Brühlmann, CBO, Proteomedix
bruehlmann@proteomedix.com, +41 44 733 40 90